ALYFTREK's Patent Shield Extended: FDA Calls for Challenges
Published Date: 2/13/2026
Notice
Summary
The FDA has set the official review period for ALYFTREK, a new drug, so its patent holder can apply for extra patent time. This helps the company protect their invention longer, potentially delaying generic competition and affecting drug prices. If anyone thinks the dates are wrong or wants to challenge the company’s review speed, they have until April or August 2026 to speak up.
Analyzed Economic Effects
2 provisions identified: 1 benefits, 1 costs, 0 mixed.
Drug patent review period set
The FDA found that ALYFTREK had a regulatory review period of 5,335 days (5,102 days testing phase and 233 days approval phase). The testing phase began May 15, 2010; the new drug application was submitted May 2, 2024; and FDA approved the application on December 20, 2024. The applicant is seeking 1,826 days of patent term extension, and FDA’s determination establishes the maximum potential length of a patent extension.
Public comment and petition windows
Anyone who thinks the published dates are wrong can submit comments requesting a redetermination by April 14, 2026. Any interested person may petition FDA about whether the applicant acted with due diligence during the regulatory review period by August 12, 2026. Instructions for electronic and written submissions are provided in the notice.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in